Evogene Ltd. Earnings Recaps
Q3 2025
Nov 21, 2025
Evogene reported a significant reduction in operating expenses, reflecting the successful implementation of its strategic shift towards computational chemistry, while also generating income from divestitures.
Key takeaways
- Operating expenses decreased to approximately $2.9 million, down from $6.6 million in Q3 2024, following a cost reduction plan.
- The sale of Lavie Bio's majority activities contributed approximately $7.9 million in income for the third quarter.
- Total operating loss improved to around $8.8 million, compared to a loss of $15.3 million in the same period last year.
- Cash and short-term deposits stand at approximately $16 million, bolstered by recent divestitures.
- Revenue for the first nine months of 2025 was approximately $3.5 million, reflecting lower AgPlenus revenue but increased seed sales from Casterra.
Q2 2025
Aug 19, 2025
Evogene reported significant revenue growth and reduced operating expenses amid a strategic transition focused on its ChemPass AI platform. The company anticipates realizing full benefits from cost-cutting measures in the latter half of 2025.
Key takeaways
- Total revenues rose to approximately $3.2 million for H1 2025, up from $2.3 million in H1 2024, driven by strong seed sales from Casterra.
- Research and development expenses decreased to $4.8 million due to reduced activities at Biomica and the discontinuation of Canonic.
- Total operating expenses fell significantly to $7.7 million, down from $11.1 million, primarily due to streamlined operations and a lower headcount.
- Evogene began a strategic shift towards enhancing its ChemPass AI platform, resulting in the successful completion of a generative AI model for small molecule design in collaboration with Google Cloud.